In vitro and in vivo long term release of apomorphine from polymer matrices

Japanese Journal of Pharmacology

Volumn 84, Issue 1, 2000, Pages 36-43

  Raasch, W ^a   Slotty, C ^a   Dominiak, P ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Apomorphine; Ethylene vinyl acetate polymeric delivery system; Kinetic study; Parkinson's disease

Indexed keywords

APOMORPHINE; ETHYLENE VINYL ACETATE COPOLYMER; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG OVERDOSE; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARKINSON DISEASE; RAT;

EID: 0033780460     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.84.36     Document Type: Article

References (33)

1. Lisuride infusion pump. A device for the treatment of motor fluctuations in Parkinson's disease
2. On-off fluctuations in Parkinson's disease: A clinical and neuropharmacological study
3. Chronic intrastriatal dopamine infusion in rats with unilateral lesions of the substantia nigra
4. Controlled release levodopa/carbidopa. I. Sinnet CR3 treatment of response fluctuations in Parkinson's disease
5. Clinical and biochemical studies with controlled release levodopa/carbidopa
6. The hydrodynamically balanced system: A novel principle of controlled drug release
7. Fluctuations of disability in Parkinson's disease-clinical aspects
8. Complicated response fluctuations in Parkinson's disease: Response to intravenous infusion of levodopa
9. The modern management of Parkinson's disease
10. Apomorphine in Parkinson's disease
11. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease: Long term experience in 20 patients
12. Determination of apomorphine in rat plasma and brain by high-performance liquid chromatography with electrochemical detection
13. Time-course of apomorphine in the brain of the immature rat after apomorphine injection
14. Structural effects in drug distribution of apomorphine analogs
15. Biological disposition of apomorphine. III: Kinetics of metabolism of apomorphine and role of the liver in its biotransformation
16. Preclinical studies of the pharmacology of apomorphine
17. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease
18. Interactions of apomorphine with serum and tissue proteins
19. Polymers for the sustained release of makromolecules
20. Polymers for sustained macromolecular release: Procedures to fabricate reproducible delivery systems and control release kinetics
21. Controlled release of dopamine from a polymeric brain implant. In vitro characterization
22. Levodopa delivery from controlled-release polymer matrix: Delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats
23. A model of dissolution-controlled solute release from porous drug delivery polymeric systems
24. Peripheral pharmacokinetics of apomorphine in humans
25. Clues to the mechanism underlying dopamine cell death in Parkinson's disease
26. Side effects of subcutaneous apomorphine in Parkinson's disease
27. Subcutaneous apomorphine in Parkinson's disease
28. Side-effects of subcutaneous apomorphine in Parkinson's disease
29. Apomorphine in the diagnosis and treatment of parkinsonian tremor
30. The clinical use of apomorphine in Parkinson's disease
31. The short-duration response to apomorphine: Implications for the mechanism of dopaminergic effects in parkinsonism
32. Subcutaneous apomorphine in parkinsonian on-off oscillations
33. Subcutaneous apomorphine in the treatment of Parkinson's disease